Trait Document

Save to PDF
Trait Profile

Gaucher disease

Other Names: Glucocerebrosidase deficiency, glucosylceramidase deficiency

Gaucher disease is a genetic condition characterized by the body’s inability to break down a certain fatty substance called glucocerebroside. It is caused by mutations in the GBA gene that makes the beta-glucocerebrosidase protein.

Characteristics of Gaucher disease
Individuals with Gaucher disease cannot properly breakdown a certain fatty substance called glucocerebroside (GL-1). GL-1 cannot be broken down because the enzyme, beta-glucocerebrosidase, is not working properly. Without enough enzyme, GL-1 builds up in various tissues of the body. Gaucher disease is divided into 3 main types: type 1, type 2, and type 3. Type 1 is the most common and is also referred to as "non-neuronopathic" Gaucher disease. Individuals with Gaucher disease type 1 often have an enlarged spleen and liver, and bone disease. Enlargement of the spleen and liver can cause abdominal pain and in rare cases, spleen rupture or liver failure. Individuals with Gaucher disease type 1 often have pain in their joints and bones and are at increased risk for low bone mineral density, which then causes their bones to break easily. Many individuals with Gaucher disease type 1 have anemia (i.e., low blood count), and bruise very easily because their blood cells do not clot properly. They also often have lung problems (e.g., pulmonary hypertension).
In Gaucher disease type 1, the brain and spinal cord (the central nervous system) are usually not affected, whereas in the rarer types (type 2 and type 3, also called the "neuronopathic" forms of Gaucher disease), the central nervous system is affected. Type 2 and type 3 Gaucher disease typically diagnosed in early childhood (i.e., before age 2).

A diagnosis of Gaucher disease can be made by measuring the beta-glucocerebrosidase enzyme activity from a blood sample. A person with Gaucher disease often has deficient (low) enzyme activity. A diagnosis of Gaucher disease can also be done by genetic testing for changes or mutations in the GBA gene. This gene makes the beta-glucocerebrosidase enzyme that is responsible for breaking down the fatty substance GL-1. Mutations in the GBA gene prevent the enzyme from working properly, resulting in a build-up of GL-1 in various organs of the body.

Management of Gaucher disease includes routine blood tests to monitor for anemia and clotting ability, bone scans and x-rays to monitor bone disease, MRIs to monitor the spleen and liver, and regular comprehensive clinical examinations by a healthcare provider familiar with Gaucher disease.
Enzyme replacement therapy (ERT) is a medical treatment available for Gaucher disease. ERT provides the beta-glucocerebrosidase enzyme that is missing in individuals with Gaucher disease through regular intravenous (IV) infusions. ERT is a lifelong treatment for Gaucher disease and is not a cure. There is also substrate reduction therapy for Gaucher disease which involves taking a medication that is designed to reduce the amount of the fatty substance GL-1 that accumulates in a cell.

Mode of inheritance
Gaucher disease is inherited in an autosomal recessive pattern. This means that an individual has to inherit two GBA mutations (i.e., one from each parent) to be affected with Gaucher disease. If both parents are carriers of a GBA mutation, they have a 1 in 4 (25%) chance with each pregnancy of having a child with Gaucher disease.

Risk to family members
Parents of a child with Gaucher disease are carriers of Gaucher disease. If a sibling of a child with Gaucher disease is unaffected, he/she has a 2 in 3 (or 66%) chance of being a carrier of Gaucher disease.

Special considerations

Genetics Home Reference: Gaucher Disease
National Gaucher Foundation

Aerts, Johannes MFG et al. (2007). Gaucher Disease Futerman, Anthony and Zimran, Ari eds. Boca Raton: Taylor & Francis Group, LLC. Print.
Cox, TM et al. (2008)."Management of non-neuronopathic Gaucher disease with special reference to pregnancy, Splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring." Journal of Inherited Metabolic Diseases 31(3): 319-336.
Kaplan, P. et al. (2013)."Revised recommendations of the management of Gaucher disease in children." European Journal of Pediatrics 172(4): 447-458.
Pastores GM, Hughes DA. (Updated 21 July 2011). Gaucher Disease. In: GeneReviews at GeneTests Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1997-2013. Available at Accessed [05/14/2013].



Created by:Valynne Long, MS, CGC

Edited by:Seema Jamal, MSc, LCGC

Your Session Is About to Expire

To keep your account secure, your My46 session expires after one hour of inactivity. If you are still using the site, click below to extend your session.